1,160 research outputs found

    Unconventional markers of Alzheimer Disease

    Get PDF
    Although typically conceptualized as a cortical disease, recent neuropathological and neuroimaging investigations on Alzheimer Disease suggest that other brain structures play an important role in the pathogenesis and progression of this devastating condition. In this thesis, we explored novel markers of Alzheimer Disease beyond the classical cortical pathology measures of amyloid, tau, and neurodegeneration. We focused on the role of white matter abnormalities, assessed with magnetic resonance imaging but also with amyloid positron emission tomography, in predicting early pathologic changes and disease progression, as well as on the added value of cognition to amyloid, tau, and neurodegeneration biomarkers. Overall, we found that these unconventional markers provide useful information to detect the earliest pathological changes of the disease, providing a better understanding of the mechanisms that lead to amyloid deposition and cognitive decline

    Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration.

    Get PDF
    OBJECTIVE: To quantify the regional and global cerebral atrophy rates and assess acceleration rates in healthy controls, subjects with mild cognitive impairment (MCI), and subjects with mild Alzheimer disease (AD). METHODS: Using 0-, 6-, 12-, 18-, 24-, and 36-month MRI scans of controls and subjects with MCI and AD from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, we calculated volume change of whole brain, hippocampus, and ventricles between all pairs of scans using the boundary shift integral. RESULTS: We found no evidence of acceleration in whole-brain atrophy rates in any group. There was evidence that hippocampal atrophy rates in MCI subjects accelerate by 0.22%/year2 on average (p = 0.037). There was evidence of acceleration in rates of ventricular enlargement in subjects with MCI (p = 0.001) and AD (p < 0.001), with rates estimated to increase by 0.27 mL/year2 (95% confidence interval 0.12, 0.43) and 0.88 mL/year2 (95% confidence interval 0.47, 1.29), respectively. A post hoc analysis suggested that the acceleration of hippocampal loss in MCI subjects was mainly driven by the MCI subjects that were observed to progress to clinical AD within 3 years of baseline, with this group showing hippocampal atrophy rate acceleration of 0.50%/year2 (p = 0.003). CONCLUSIONS: The small acceleration rates suggest a long period of transition to the pathologic losses seen in clinical AD. The acceleration in hippocampal atrophy rates in MCI subjects in the ADNI seems to be driven by those MCI subjects who concurrently progressed to a clinical diagnosis of AD

    EANM-EAN recommendations for the use of brain 18 F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in neurodegenerative cognitive impairment and dementia: Delphi consensus

    Get PDF
    BACKGROUND: Recommendations for using FDG-PET to support the diagnosis of dementing neurodegenerative disorders are sparse and poorly structured. METHODS: We defined 21 questions on diagnostic issues and on semi-automated analysis to assist visual reading. Literature was reviewed to assess study design, risk of bias, inconsistency, imprecision, indirectness and effect size. Critical outcomes were sensitivity, specificity, accuracy, positive/negative predictive value, area under the receiving operating characteristic curve, and positive/negative likelihood ratio of FDG-PET in detecting the target conditions. Using the Delphi method, an expert panel voted for/against the use of FDG-PET based on published evidence and expert opinion. RESULTS: Of the 1435 papers, 58 provided proper quantitative assessment of test performance. The panel agreed on recommending FDG-PET for 14 questions: diagnosing mild cognitive impairment due to Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD) or dementia with Lewy bodies (DLB); diagnosing atypical AD and pseudodementia; differentiating between AD and DLB, FTLD, or vascular dementia, between DLB and FTLD, and between Parkinson's disease (PD) and progressive supranuclear palsy; suggesting underlying pathophysiology in corticobasal degeneration and progressive primary aphasia, and cortical dysfunction in PD; using semi-automated assessment to assist visual reading. Panelists did not support FDG-PET use for preclinical stages of neurodegenerative disorders, for amyotrophic lateral sclerosis (ALS) and Huntington disease (HD) diagnoses, and ALS or HD-related cognitive decline. CONCLUSIONS: Despite limited formal evidence, panelists deemed FDG-PET useful in the early and differential diagnosis of the main neurodegenerative disorders, and semiautomated assessment helpful to assist visual reading. These decisions are proposed as interim recommendations. This article is protected by copyright. All rights reserved

    Regional association of pCASL-MRI with FDG-PET and PiB-PET in people at risk for autosomal dominant Alzheimer's disease.

    Get PDF
    Autosomal dominant Alzheimer's disease (ADAD) is a small subset of Alzheimer's disease that is genetically determined with 100% penetrance. It provides a valuable window into studying the course of pathologic processes that leads to dementia. Arterial spin labeling (ASL) MRI is a potential AD imaging marker that non-invasively measures cerebral perfusion. In this study, we investigated the relationship of cerebral blood flow measured by pseudo-continuous ASL (pCASL) MRI with measures of cerebral metabolism (FDG PET) and amyloid deposition (Pittsburgh Compound B (PiB) PET). Thirty-one participants at risk for ADAD (age 39&nbsp;±&nbsp;13&nbsp;years, 19 females) were recruited into this study, and 21 of them received both MRI and FDG and PiB PET scans. Considerable variability was observed in regional correlations between ASL-CBF and FDG across subjects. Both regional hypo-perfusion and hypo-metabolism were associated with amyloid deposition. Cross-sectional analyses of each biomarker as a function of the estimated years to expected dementia diagnosis indicated an inverse relationship of both perfusion and glucose metabolism with amyloid deposition during AD development. These findings indicate that neurovascular dysfunction is associated with amyloid pathology, and also indicate that ASL CBF may serve as a sensitive early biomarker for AD. The direct comparison among the three biomarkers provides complementary information for understanding the pathophysiological process of AD

    Evaluation of recurrent glioma and Alzheimer’s disease using novel multimodal brain image processing and analysis

    Get PDF
    Novel analysis techniques were applied to two different sets of multi-modality brain images. Localised metabolic rate within the hippocampus was assessed for its ability to differentiate between groups of healthy, mildly cognitively impaired, and Alzheimer’s disease brains, and an investigation of its potential clinical diagnostic utility was conducted. Relative uptake and retention of two PET tracers (11Carbon Methionine and 18Fluoro Thymidine) in a post-treatment glioma patient cohort was utilized to perform survival prediction analysis

    Cortical thickness analysis in early diagnostics of Alzheimer's disease

    Get PDF

    Ensemble of classifiers based data fusion of EEG and MRI for diagnosis of neurodegenerative disorders

    Get PDF
    The prevalence of Alzheimer\u27s disease (AD), Parkinson\u27s disease (PD), and mild cognitive impairment (MCI) are rising at an alarming rate as the average age of the population increases, especially in developing nations. The efficacy of the new medical treatments critically depends on the ability to diagnose these diseases at the earliest stages. To facilitate the availability of early diagnosis in community hospitals, an accurate, inexpensive, and noninvasive diagnostic tool must be made available. As biomarkers, the event related potentials (ERP) of the electroencephalogram (EEG) - which has previously shown promise in automated diagnosis - in addition to volumetric magnetic resonance imaging (MRI), are relatively low cost and readily available tools that can be used as an automated diagnosis tool. 16-electrode EEG data were collected from 175 subjects afflicted with Alzheimer\u27s disease, Parkinson\u27s disease, mild cognitive impairment, as well as non-disease (normal control) subjects. T2 weighted MRI volumetric data were also collected from 161 of these subjects. Feature extraction methods were used to separate diagnostic information from the raw data. The EEG signals were decomposed using the discrete wavelet transform in order to isolate informative frequency bands. The MR images were processed through segmentation software to provide volumetric data of various brain regions in order to quantize potential brain tissue atrophy. Both of these data sources were utilized in a pattern recognition based classification algorithm to serve as a diagnostic tool for Alzheimer\u27s and Parkinson\u27s disease. Support vector machine and multilayer perceptron classifiers were used to create a classification algorithm trained with the EEG and MRI data. Extracted features were used to train individual classifiers, each learning a particular subset of the training data, whose decisions were combined using decision level fusion. Additionally, a severity analysis was performed to diagnose between various stages of AD as well as a cognitively normal state. The study found that EEG and MRI data hold complimentary information for the diagnosis of AD as well as PD. The use of both data types with a decision level fusion improves diagnostic accuracy over the diagnostic accuracy of each individual data source. In the case of AD only diagnosis, ERP data only provided a 78% diagnostic performance, MRI alone was 89% and ERP and MRI combined was 94%. For PD only diagnosis, ERP only performance was 67%, MRI only was 70%, and combined performance was 78%. MCI only diagnosis exhibited a similar effect with a 71% ERP performance, 82% MRI performance, and 85% combined performance. Diagnosis among three subject groups showed the same trend. For PD, AD, and normal diagnosis ERP only performance was 43%, MRI only was 66%, and combined performance was 71%. The severity analysis for mild AD, severe AD, and normal subjects showed the same combined effect
    corecore